Study finds aciclovir benefit

teaser

Long-term use of suppressive prophylactic aciclovir appears to prevent the emergence of drug-resistant herpes simplex virus disease in haematopoietic stem-cell transplant, a study has concluded.

This study examined the effect of long-term use of suppressive aciclovir (ACV) on overall herpes simplex virus (HSV) disease and ACV-resistant HSV disease.

Data were obtained from three consecutive cohorts of haematopoietic stem-cell transplant (HCT) recipients (n=2,049):

• Cohort 1 received ACV for 30 days after HCT.

• Cohort 2 received ACV for one year after HCT.

• Cohort 3 received ACV for an extended period (>1 year) if immunosuppression continued after one year.

The study reported the following results:

Two-year probability of HSV disease:

↓Article continues below this sponsored advert↓

Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.

Agenda Register

↑Advertisement↑

• 31.6% (95% CI, 28 to 35%) in cohort 1.

• 3.9% (2.7–5.2%) in cohort 2.

• 0% in cohort 3.

ACV-resistant HSV disease developed in:

• 10 patients in cohort 1 (two-year probability, 1.3%; 0.8–2.7%).

• Two patients in cohort 2 (0.2%; 0–0.8%).

• 0 patients in cohort 3.

J Inf Dis 2007;196:266-70